

Jeffrey R Curtis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6658027/publications.pdf>

Version: 2024-02-01

334
papers

22,089
citations

15495

65
h-index

11303

136
g-index

338
all docs

338
docs citations

338
times ranked

19508
citing authors

#	ARTICLE	IF	CITATIONS
1	2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1-26.	2.9	1,880
2	2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 625-639.	1.5	1,413
3	American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2008, 59, 762-784.	6.7	1,311
4	The Recent Prevalence of Osteoporosis and Low Bone Mass in the United States Based on Bone Mineral Density at the Femoral Neck or Lumbar Spine. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 2520-2526.	3.1	1,305
5	2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016, 68, 1-25.	1.5	890
6	Population-based assessment of adverse events associated with long-term glucocorticoid use. <i>Arthritis and Rheumatism</i> , 2006, 55, 420-426.	6.7	448
7	Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor \pm antagonists. <i>Arthritis and Rheumatism</i> , 2007, 56, 1125-1133.	6.7	351
8	A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis trial. <i>Arthritis and Rheumatism</i> , 2012, 64, 2824-2835.	6.7	325
9	Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1253-1262.	0.5	316
10	Initiation of Tumor Necrosis Factor- \pm Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2331-9.	3.8	305
11	Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 576-582.	0.5	304
12	High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 785-791.	0.5	269
13	Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies. <i>Journal of Rheumatology</i> , 2014, 41, 837-852.	1.0	264
14	Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1920-1925.	0.5	255
15	Association Between Vaccination for Herpes Zoster and Risk of Herpes Zoster Infection Among Older Patients With Selected Immune-Mediated Diseases. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 43-9.	3.8	246
16	Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care. <i>Clinical Therapeutics</i> , 2011, 33, 679-707.	1.1	241
17	Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. <i>Arthritis Research and Therapy</i> , 2019, 21, 89.	1.6	232
18	Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1843-1847.	0.5	215

#	ARTICLE	IF	CITATIONS
19	Obesity and response to anti-tumor necrosis factor- α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2018, 13, e0195123.	1.1	196
20	Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 644-649.	0.5	183
21	Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy. <i>Arthritis and Rheumatology</i> , 2017, 69, 1960-1968.	2.9	182
22	A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries. <i>Seminars in Arthritis and Rheumatism</i> , 2010, 40, 2-14.e1.	1.6	161
23	2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures. <i>Arthritis Care and Research</i> , 2019, 71, 1540-1555.	1.5	157
24	Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination. <i>Arthritis and Rheumatology</i> , 2016, 68, 2328-2337.	2.9	150
25	Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. <i>Arthritis Care and Research</i> , 2012, 64, 1794-1803.	1.5	149
26	Development of a Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis. <i>PLoS ONE</i> , 2013, 8, e60635.	1.1	146
27	American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1. <i>Arthritis and Rheumatology</i> , 2021, 73, 1093-1107.	2.9	146
28	Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments. <i>Arthritis and Rheumatology</i> , 2016, 68, 2612-2617.	2.9	138
29	Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare. <i>Arthritis and Rheumatology</i> , 2016, 68, 56-66.	2.9	136
30	Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 831-841.	0.5	135
31	Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1400-1413.	0.5	132
32	Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer. <i>JAMA Dermatology</i> , 2016, 152, 164.	2.0	131
33	The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1301-1308.	0.5	126
34	American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3. <i>Arthritis and Rheumatology</i> , 2021, 73, e60-e75.	2.9	126
35	Death, Debility, and Destitution Following Hip Fracture. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2014, 69A, 346-353.	1.7	125
36	Changes in Lipoproteins Associated With Methotrexate Therapy or Combination Therapy in Early Rheumatoid Arthritis: Results From the Treatment of Early Rheumatoid Arthritis Trial. <i>Arthritis and Rheumatism</i> , 2013, 65, 1430-1438.	6.7	124

#	ARTICLE	IF	CITATIONS
37	Recent trends in hip fracture rates by race/ethnicity among older US adults. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 2325-2332.	3.1	121
38	Longitudinal Trends in Use of Bone Mass Measurement Among Older Americans, 1999-2005. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1061-1067.	3.1	115
39	Validity of Claims-Based Stroke Algorithms in Contemporary Medicare Data. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 611-619.	0.9	113
40	A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease. <i>Gastroenterology</i> , 2021, 161, 837-852.e9.	0.6	113
41	Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor \pm agents, a retrospective cohort study. <i>Arthritis Research and Therapy</i> , 2015, 17, 319.	1.6	106
42	Population-Based Fracture Risk Assessment and Osteoporosis Treatment Disparities by Race and Gender. <i>Journal of General Internal Medicine</i> , 2009, 24, 956-962.	1.3	101
43	Benefit of Adherence With Bisphosphonates Depends on Age and Fracture Type: Results From an Analysis of 101,038 New Bisphosphonate Users. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1435-1441.	3.1	100
44	Identification and Validation of Vertebral Compression Fractures Using Administrative Claims Data. <i>Medical Care</i> , 2009, 47, 69-72.	1.1	100
45	Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAFETY Assessment of Biologic ThERapy (SABER) Study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1942-1948.	0.5	100
46	Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. <i>RMD Open</i> , 2020, 6, e001395.	1.8	100
47	Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 489-497.	1.6	99
48	Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor- γ -Directed Therapy for Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2018, 113, 405-417.	0.2	99
49	The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1401-1406.	0.5	98
50	Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2020, 173, 870-878.	2.0	97
51	Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. <i>Arthritis Care and Research</i> , 2020, 72, 561-576.	1.5	96
52	Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 842-849.	0.9	94
53	Cardiovascular Risk in Rheumatoid Arthritis: Comparing TNF- γ Blockade with Nonbiologic DMARDs. <i>American Journal of Medicine</i> , 2013, 126, 730.e9-730.e17.	0.6	94
54	Risks of Herpes Zoster in Patients With Rheumatoid Arthritis According to Biologic Disease-Modifying Therapy. <i>Arthritis Care and Research</i> , 2015, 67, 731-736.	1.5	94

#	ARTICLE	IF	CITATIONS
55	The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. <i>Arthritis Research and Therapy</i> , 2011, 13, R174.	1.6	92
56	Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1813-1818.	0.5	90
57	EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1628-1639.	0.5	89
58	Improving the Prediction of Medication Compliance. <i>Medical Care</i> , 2009, 47, 334-341.	1.1	87
59	Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1065-1071.	0.5	79
60	Challenges in Improving the Quality of Osteoporosis Care for Long-term Glucocorticoid Users. <i>Archives of Internal Medicine</i> , 2007, 167, 591.	4.3	78
61	Adherence and Persistence with Methotrexate in Rheumatoid Arthritis: A Systematic Review. <i>Journal of Rheumatology</i> , 2016, 43, 1997-2009.	1.0	78
62	Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1255-1265.	0.5	77
63	The incidence of gastrointestinal perforations among rheumatoid arthritis patients. <i>Arthritis and Rheumatism</i> , 2011, 63, 346-351.	6.7	71
64	Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids. <i>Arthritis Care and Research</i> , 2019, 71, 1249-1254.	1.5	71
65	Modifiable Factors Associated with Allopurinol Adherence and Outcomes Among Patients with Gout in an Integrated Healthcare System. <i>Journal of Rheumatology</i> , 2015, 42, 504-512.	1.0	69
66	Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs. <i>Arthritis Care and Research</i> , 2015, 67, 1671-1678.	1.5	67
67	Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty. <i>Arthritis Care and Research</i> , 2017, 69, 1845-1854.	1.5	66
68	Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2011, 13, R155.	1.6	65
69	Linkage of a Deidentified United States Rheumatoid Arthritis Registry With Administrative Data to Facilitate Comparative Effectiveness Research. <i>Arthritis Care and Research</i> , 2014, 66, 1790-1798.	1.5	65
70	Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1293-1301.e5.	2.4	65
71	Association between anti-TNF therapy and interstitial lung disease. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 394-402.	0.9	64
72	Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report. <i>Special Care in Dentistry</i> , 2010, 30, 77-82.	0.4	63

#	ARTICLE	IF	CITATIONS
73	Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 341-347.	0.5	63
74	Identifying types of nursing facility stays using medicare claims data: an algorithm and validation. <i>Health Services and Outcomes Research Methodology</i> , 2010, 10, 100-110.	0.8	62
75	The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 430-436.	0.5	61
76	Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 285-291.	0.5	61
77	American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2. <i>Arthritis and Rheumatology</i> , 2021, 73, e30-e45.	2.9	61
78	Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users. <i>Pharmacoepidemiology and Drug Safety</i> , 2006, 15, 710-718.	0.9	59
79	Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 1819-1828.	1.5	59
80	Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations. <i>Arthritis and Rheumatism</i> , 2012, 64, 630-638.	6.7	59
81	Increased pretreatment serum IFN- γ /IL-6 ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1757-1762.	0.5	59
82	Changing Trends in Opioid Use Among Patients With Rheumatoid Arthritis in the United States. <i>Arthritis and Rheumatology</i> , 2017, 69, 1733-1740.	2.9	59
83	Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 231.	0.8	58
84	Is Withholding Osteoporosis Medication After Fracture Sometimes Rational? A Comparison of the Risk for Second Fracture Versus Death. <i>Journal of the American Medical Directors Association</i> , 2010, 11, 584-591.	1.2	57
85	Characteristics and Health-care Utilization History of Patients With Bronchiectasis in US Medicare Enrollees With Prescription Drug Plans, 2006 to 2014. <i>Chest</i> , 2018, 154, 1311-1320.	0.4	57
86	Advancing the Science and Practice of Medication Adherence. <i>Journal of General Internal Medicine</i> , 2018, 33, 216-222.	1.3	57
87	Concerns, Healthcare Use, and Treatment Interruptions in Patients With Common Autoimmune Rheumatic Diseases During the COVID-19 Pandemic. <i>Journal of Rheumatology</i> , 2021, 48, 603-607.	1.0	56
88	Placebo Adherence, Clinical Outcomes, and Mortality in the Women's Health Initiative Randomized Hormone Therapy Trials. <i>Medical Care</i> , 2011, 49, 427-435.	1.1	55
89	Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 76.	0.7	55
90	Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids: clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole. <i>Arthritis Research and Therapy</i> , 2019, 21, 207.	1.6	54

#	ARTICLE	IF	CITATIONS
91	Management of Osteoporosis among the Elderly with Other Chronic Medical Conditions. <i>Drugs and Aging</i> , 2012, 29, 549-564.	1.3	53
92	Central DXA utilization shifts from office-based to hospital-based settings among medicare beneficiaries in the wake of reimbursement changes. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 858-864.	3.1	53
93	Wrist Fracture and Risk of Subsequent Fracture: Findings from the Women's Health Initiative Study. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 2086-2095.	3.1	53
94	Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients. <i>Arthritis Care and Research</i> , 2019, 71, 1004-1018.	1.5	53
95	Risk of Hospitalized Infection Among Rheumatoid Arthritis Patients Concurrently Treated With a Biologic Agent and Denosumab. <i>Arthritis and Rheumatology</i> , 2015, 67, 1456-1464.	2.9	51
96	Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus low-risk rheumatoid arthritis patients. <i>Arthritis Care and Research</i> , 2012, 64, 1480-1489.	1.5	49
97	Trends in the Use of Biologic Agents Among Rheumatoid Arthritis Patients Enrolled in the US Medicare Program. <i>Arthritis Care and Research</i> , 2013, 65, 1743-1751.	1.5	49
98	Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial. <i>American Journal of Medicine</i> , 2019, 132, 354-361.	0.6	49
99	American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4. <i>Arthritis and Rheumatology</i> , 2022, 74, e21-e36.	2.9	49
100	Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy. <i>Arthritis Care and Research</i> , 2012, 64, 1282-1291.	1.5	48
101	Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1012-1016.	0.5	48
102	Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients With Selected Conditions. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1881-1888.	3.1	47
103	Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study. <i>Arthritis Research and Therapy</i> , 2018, 20, 60.	1.6	46
104	Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1522-1529.	0.5	46
105	The relationship between bisphosphonate adherence and fracture: Is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 683-688.	3.1	45
106	Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials. <i>RMD Open</i> , 2019, 5, e000942.	1.8	45
107	What Proportion of Incident Radiographic Vertebral Fractures in Older Men Is Clinically Diagnosed and Vice Versa: A Prospective Study. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1500-1503.	3.1	44
108	The Design and Validation of a New Algorithm to Identify Incident Fractures in Administrative Claims Data. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1798-1807.	3.1	44

#	ARTICLE	IF	CITATIONS
109	Adaptation of Bayesian Data Mining Algorithms to Longitudinal Claims Data. <i>Medical Care</i> , 2008, 46, 969-975.	1.1	43
110	The delivery of evidence-based preventive care for older Americans with arthritis. <i>Arthritis Research and Therapy</i> , 2010, 12, R144.	1.6	43
111	Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: Experience from a large US cohort. <i>Arthritis Care and Research</i> , 2011, 63, 1672-1679.	1.5	43
112	Tocilizumab in rheumatoid arthritis: A case study of safety evaluations of a large postmarketing data set from multiple data sources. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 381-388.	1.6	43
113	International Consortium for Health Outcome Measurement Set of Outcomes That Matter to People Living With Inflammatory Arthritis: Consensus From an International Working Group. <i>Arthritis Care and Research</i> , 2019, 71, 1556-1565.	1.5	43
114	Impact of Biologic Agents With and Without Concomitant Methotrexate and at Reduced Doses in Older Rheumatoid Arthritis Patients. <i>Arthritis Care and Research</i> , 2015, 67, 624-632.	1.5	41
115	Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies. <i>Arthritis Research and Therapy</i> , 2021, 23, 1.	1.6	41
116	Osteoporosis Care in the United States After Declines in Reimbursements for DXA. <i>Journal of Clinical Densitometry</i> , 2010, 13, 352-360.	0.5	40
117	Commentary: The Five Ws of a Fracture Liaison Service: Why, Who, What, Where, and How? In Osteoporosis, We Reap What We Sow. <i>Current Osteoporosis Reports</i> , 2013, 11, 365-368.	1.5	38
118	Osteoporosis medication adherence: Physician perceptions vs. patients' utilization. <i>Bone</i> , 2013, 55, 1-6.	1.4	37
119	Validation Study of Medicare Claims to Identify Older US Adults With CKD Using the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. <i>American Journal of Kidney Diseases</i> , 2015, 65, 249-258.	2.1	37
120	Severity of Hypertension Mediates the Association of Hyperuricemia With Stroke in the REGARDS Case Cohort Study. <i>Hypertension</i> , 2020, 75, 246-256.	1.3	37
121	Adherence with intravenous zoledronate and intravenous ibandronate in the United States medicare population. <i>Arthritis Care and Research</i> , 2012, 64, 1054-1060.	1.5	36
122	Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis. <i>Chest</i> , 2017, 152, 1120-1127.	0.4	36
123	Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 1606-1616.	1.5	35
124	Burden and trajectory of multimorbidity in rheumatoid arthritis: a matched cohort study from 2006 to 2015. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 286-292.	0.5	35
125	Which patient-reported outcomes do rheumatology patients find important to track digitally? A real-world longitudinal study in ArthritisPower. <i>Arthritis Research and Therapy</i> , 2021, 23, 53.	1.6	35
126	Physician preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease activity. <i>Arthritis Care and Research</i> , 2010, 62, 101-107.	1.5	34

#	ARTICLE	IF	CITATIONS
127	Converting modified health assessment questionnaire (HAQ), multidimensional HAQ, and HAQII scores into original HAQ scores using models developed with a large cohort of rheumatoid arthritis patients. <i>Arthritis Care and Research</i> , 2010, 62, 1481-1488.	1.5	34
128	Patient perspectives on achieving T2T goals: A critical examination of patient reported outcomes. <i>Arthritis Care and Research</i> , 2013, 65, n/a-n/a.	1.5	34
129	Herpes Zoster as a Risk Factor for Incident Giant Cell Arteritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 2351-2358.	2.9	34
130	Perspectives of Rheumatoid Arthritis Patients on Electronic Communication and Patient-Reported Outcome Data Collection: A Qualitative Study. <i>Arthritis Care and Research</i> , 2019, 71, 80-87.	1.5	34
131	Tumor necrosis factor inhibitors and infection complications. <i>Current Rheumatology Reports</i> , 2008, 10, 383-389.	2.1	33
132	Predicting future response to certolizumab pegol in rheumatoid arthritis patients: Features at 12 weeks associated with low disease activity at 1 year. <i>Arthritis Care and Research</i> , 2012, 64, 658-667.	1.5	33
133	Use of Oral and Subcutaneous Methotrexate in Rheumatoid Arthritis Patients in the United States. <i>Arthritis Care and Research</i> , 2014, 66, 1604-1611.	1.5	33
134	PROMIS Fatigue short forms are reliable and valid in adults with rheumatoid arthritis. <i>Journal of Patient-Reported Outcomes</i> , 2019, 3, 14.	0.9	33
135	Digital Interventions to Build a Patient Registry for Rheumatology Research. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 173-186.	0.8	33
136	Osteoporotic fracture trends in a population of US managed care enrollees from 2007 to 2017. <i>Osteoporosis International</i> , 2020, 31, 1299-1304.	1.3	33
137	Association of Intact Parathyroid Hormone Levels with Subsequent Hip BMD Loss: The Osteoporotic Fractures in Men (MrOS) Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1937-1944.	1.8	32
138	Vaccinations for Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2014, 16, 431.	2.1	32
139	Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (CATCH). <i>PLoS ONE</i> , 2015, 10, e0135327.	1.1	32
140	Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2017, 69, 313-322.	1.5	32
141	Routine Use of Quantitative Disease Activity Measurements among US Rheumatologists: Implications for Treat-to-target Management Strategies in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 40-44.	1.0	32
142	Disruptions in Rheumatology Care and the Rise of Telehealth in Response to the COVID-19 Pandemic in a Community Practice-Based Network. <i>Arthritis Care and Research</i> , 2021, 73, 1153-1161.	1.5	32
143	Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 206-212.	0.5	31
144	Patient Governance in a Patient-Powered Research Network for Adult Rheumatologic Conditions. <i>Medical Care</i> , 2018, 56, S16-S21.	1.1	31

#	ARTICLE	IF	CITATIONS
145	Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor. <i>Journal of Rheumatology</i> , 2019, 46, 475-482.	1.0	31
146	Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis. <i>European Respiratory Journal</i> , 2019, 54, 1801896.	3.1	31
147	Bridging the Osteoporosis Quality Chasm. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 3-7.	3.1	30
148	DXA Utilization Between 2006 and 2012 in Commercially Insured Younger Postmenopausal Women. <i>Journal of Clinical Densitometry</i> , 2015, 18, 145-149.	0.5	30
149	Incidence and prevalence of axial spondyloarthritis: methodologic challenges and gaps in the literature. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 263-274.	0.4	30
150	Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2017, 69, 1526-1534.	1.5	29
151	SARS CoV-2 infection among patients using immunomodulatory therapies. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 269-271.	0.5	29
152	Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission. <i>Arthritis and Rheumatology</i> , 2021, 73, 759-768.	2.9	29
153	Diagnostic Prevalence of Ankylosing Spondylitis Using Computerized Health Care Data, 1996 to 2009: Underrecognition in a US Health Care Setting. , 2016, 20, 15-151.		28
154	Estimating Effectiveness and Cost of Biologics for Rheumatoid Arthritis: Application of a Validated Algorithm to Commercial Insurance Claims. <i>Clinical Therapeutics</i> , 2014, 36, 996-1004.	1.1	27
155	Cost-Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016, 68, 1751-1757.	1.5	27
156	Longterm Effectiveness of Herpes Zoster Vaccine among Patients with Autoimmune and Inflammatory Diseases. <i>Journal of Rheumatology</i> , 2017, 44, 1083-1087.	1.0	27
157	Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 113.	0.8	26
158	Cost and Effectiveness of Biologics for Rheumatoid Arthritis in a Commercially Insured Population. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 318-328.	0.5	26
159	Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication. <i>ClinicoEconomics and Outcomes Research</i> , 2016, Volume 8, 707-715.	0.7	26
160	Agreement between Medicare pharmacy claims, self-report, and medication inventory for assessing lipid-lowering medication use. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 827-835.	0.9	26
161	Survival rates of cancer patients with and without rheumatic disease: a retrospective cohort analysis. <i>BMC Cancer</i> , 2016, 16, 381.	1.1	26
162	The effect of disease-modifying antirheumatic drugs on vaccine immunogenicity in adults. <i>Cleveland Clinic Journal of Medicine</i> , 2020, 87, 695-703.	0.6	26

#	ARTICLE	IF	CITATIONS
163	Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 390-400.	0.4	26
164	Persistence and Dose Escalation of Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 1935-1943.	1.0	25
165	Validity of Privacy-Protecting Analytical Methods That Use Only Aggregate-Level Information to Conduct Multivariable-Adjusted Analysis in Distributed Data Networks. <i>American Journal of Epidemiology</i> , 2019, 188, 709-723.	1.6	25
166	Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 206-213.	0.5	25
167	Herpes Zoster and the Risk of Stroke in Patients With Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , 2017, 69, 439-446.	2.9	24
168	Characteristics, Comorbidities, and Outcomes of SARS-CoV-2 Infection in Patients With Autoimmune Conditions Treated With Systemic Therapies: A Population-based Study. <i>Journal of Rheumatology</i> , 2022, 49, 320-329.	1.0	24
169	Injection-site burning and stinging in patients with rheumatoid arthritis using injectable biologics. <i>Current Medical Research and Opinion</i> , 2011, 27, 71-78.	0.9	23
170	Optimal Use of Available Claims to Identify a Medicare Population Free of Coronary Heart Disease. <i>American Journal of Epidemiology</i> , 2015, 182, 808-819.	1.6	23
171	Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: a population-based study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 386-392.	0.5	23
172	Do Patients With Moderate or High Disease Activity Escalate Rheumatoid Arthritis Therapy According to Treat-to-Target Principles? Results From the Rheumatology Informatics System for Effectiveness Registry of the American College of Rheumatology. <i>Arthritis Care and Research</i> , 2020, 72, 166-175.	1.5	23
173	Primary Prophylaxis for <i>Pneumocystis jirovecii</i> Pneumonia in Patients Receiving Rituximab. <i>Chest</i> , 2022, 161, 1201-1210.	0.4	23
174	Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis. <i>Journal of Medical Economics</i> , 2014, 17, 555-566.	1.0	22
175	Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study. <i>Clinical Rheumatology</i> , 2018, 37, 2331-2340.	1.0	22
176	Importance of Recent Fracture as Predictor of Imminent Fracture Risk. <i>Current Osteoporosis Reports</i> , 2018, 16, 738-745.	1.5	22
177	Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting. <i>RMD Open</i> , 2019, 5, e001013.	1.8	22
178	Racial Disparities Exist in Outcomes After Major Fragility Fractures. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1803-1810.	1.3	22
179	Physicians' explanations for apparent gaps in the quality of rheumatology care: Results from the US Medicare Physician Quality Reporting System. <i>Arthritis Care and Research</i> , 2013, 65, 235-243.	1.5	21
180	A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1429-1430.	0.5	21

#	ARTICLE	IF	CITATIONS
181	A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol. <i>Arthritis and Rheumatology</i> , 2015, 67, 3104-3112.	2.9	21
182	Studies with herpes zoster vaccines in immune compromised patients. <i>Expert Review of Vaccines</i> , 2017, 16, 1217-1230.	2.0	21
183	Use of ICD-10 diagnosis codes to identify seropositive and seronegative rheumatoid arthritis when lab results are not available. <i>Arthritis Research and Therapy</i> , 2020, 22, 242.	1.6	21
184	Gout is associated with an increased risk for incident heart failure among older adults: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort study. <i>Arthritis Research and Therapy</i> , 2020, 22, 86.	1.6	21
185	Validation of ICD-9-CM codes to identify gastrointestinal perforation events in administrative claims data among hospitalized rheumatoid arthritis patients. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1150-1158.	0.9	20
186	Social media for arthritis-related comparative effectiveness and safety research and the impact of direct-to-consumer advertising. <i>Arthritis Research and Therapy</i> , 2017, 19, 48.	1.6	20
187	Timing of Abatacept Before Elective Arthroplasty and Risk of Postoperative Outcomes. <i>Arthritis Care and Research</i> , 2019, 71, 1224-1233.	1.5	20
188	Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1394-1408.	0.9	20
189	Prevention and treatment of glucocorticoid-induced osteoporosis. <i>Current Osteoporosis Reports</i> , 2007, 5, 14-21.	1.5	19
190	Does medication adherence itself confer fracture protection? An investigation of the healthy adherer effect in observational data. <i>Arthritis Care and Research</i> , 2012, 64, 1855-1863.	1.5	19
191	The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insights. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 310-319.	0.9	19
192	Influence of obesity, age, and comorbidities on the multi-biomarker disease activity test in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 472-477.	1.6	19
193	Low Persistence Rates in Patients With Rheumatoid Arthritis Treated With Triple Therapy and Adverse Drug Events Associated With Sulfasalazine. <i>Arthritis Care and Research</i> , 2019, 71, 1326-1335.	1.5	19
194	Social Distancing, Health Care Disruptions, Telemedicine Use, and Treatment Interruption During the COVID-19 Pandemic in Patients With or Without Autoimmune Rheumatic Disease. <i>ACR Open Rheumatology</i> , 2021, 3, 381-389.	0.9	19
195	Ethnic Variations in the Prevalence of Metabolic Bone Disease among HIV-Positive Patients with Lipodystrophy. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 125-131.	0.5	18
196	Predictors and persistence of new-onset clinical remission in rheumatoid arthritis patients. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 137-143.	1.6	18
197	Usability and Workflow Evaluation of the Rheumatoid Disease Activity (READY). <i>Applied Clinical Informatics</i> , 2016, 07, 1007-1024.	0.8	18
198	Gastrointestinal Perforations with Biologics in Patients with Rheumatoid Arthritis: Implications for Clinicians. <i>Drug Safety</i> , 2018, 41, 545-553.	1.4	18

#	ARTICLE	IF	CITATIONS
199	Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies. <i>Current Medical Research and Opinion</i> , 2019, 35, 1483-1493.	0.9	18
200	The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy. <i>Annals of Internal Medicine</i> , 2021, 174, 1510-1518.	2.0	18
201	The comparative effectiveness of biologics among older adults and disabled rheumatoid arthritis patients in the Medicare population. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1447-1457.	1.1	17
202	Systematic Literature Review and Meta-analysis of Tumor Necrosis Factor-Alpha Experienced Rheumatoid Arthritis. <i>Clinical Therapeutics</i> , 2017, 39, 1680-1694.e2.	1.1	17
203	Assessing a novel way to measure step count while walking using a custom mobile phone application. <i>PLoS ONE</i> , 2018, 13, e0206828.	1.1	17
204	Patterns of glucocorticoid prescribing and provider-level variation in a commercially insured incident rheumatoid arthritis population: A retrospective cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 228-236.	1.6	17
205	Identifying Minimal and Meaningful Change in a Patient-Reported Outcomes Measurement Information System for Rheumatoid Arthritis: Use of Multiple Methods and Perspectives. <i>Arthritis Care and Research</i> , 2022, 74, 588-597.	1.5	17
206	Immunosuppression and the risk of readmission and mortality in patients with rheumatoid arthritis undergoing hip fracture, abdominopelvic and cardiac surgery. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 573-580.	0.5	17
207	Recent Trends in Medication Usage for the Treatment of Juvenile Idiopathic Arthritis and the Influence of Tumor Necrosis Factor Inhibitors. <i>Journal of Rheumatology</i> , 2014, 41, 2078-2084.	1.0	16
208	A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis. <i>Pharmacoeconomics</i> , 2019, 37, 829-843.	1.7	16
209	Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 874-883.	0.9	16
210	Performance of Administrative Algorithms to Identify Interstitial Lung Disease in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 1392-1403.	1.5	16
211	A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-Î± Inhibitors: The NETWORK-004 Prospective Observational Study. <i>Rheumatology and Therapy</i> , 2021, 8, 1159-1176.	1.1	16
212	Medication Interruptions and Subsequent Disease Flares During the COVID-19 Pandemic: A Longitudinal Online Study of Patients With Rheumatic Disease. <i>Arthritis Care and Research</i> , 2022, 74, 733-740.	1.5	16
213	Identification of Multimorbidity Patterns in Rheumatoid Arthritis Through Machine Learning. <i>Arthritis Care and Research</i> , 2023, 75, 220-230.	1.5	16
214	Screening of Hyperlipidemia Among Patients With Rheumatoid Arthritis in the United States. <i>Arthritis Care and Research</i> , 2019, 71, 1593-1599.	1.5	15
215	Physical activity measured using wearable activity tracking devices associated with gout flares. <i>Arthritis Research and Therapy</i> , 2020, 22, 181.	1.6	15
216	Digital Tracking of Rheumatoid Arthritis Longitudinally (DIGITAL) Using Biosensor and Patient-Reported Outcome Data: Protocol for a Real-World Study. <i>JMIR Research Protocols</i> , 2019, 8, e14665.	0.5	15

#	ARTICLE	IF	CITATIONS
217	Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: An analysis of individual patient-level data. <i>Arthritis and Rheumatism</i> , 2011, 63, 2203-2208.	6.7	14
218	A randomized trial of a mailed intervention and self-scheduling to improve osteoporosis screening in postmenopausal women. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 2603-2610.	3.1	14
219	Identifying newly approved medications in Medicare claims data: a case study using tocilizumab. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 1214-1221.	0.9	14
220	A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial. <i>Arthritis Research and Therapy</i> , 2017, 19, 215.	1.6	14
221	Is Rheumatoid Arthritis a Cardiovascular Risk Equivalent to Diabetes Mellitus?. <i>Arthritis Care and Research</i> , 2018, 70, 1694-1699.	1.5	14
222	Data linkages between patient-powered research networks and health plans: a foundation for collaborative research. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2019, 26, 594-602.	2.2	14
223	Derivation and internal validation of a multi-biomarker-based cardiovascular disease risk prediction score for rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2020, 22, 282.	1.6	14
224	Variability in Glucocorticoid Prescribing for Rheumatoid Arthritis and the Influence of Provider Preference on Long-Term Use of Glucocorticoids. <i>Arthritis Care and Research</i> , 2021, 73, 1597-1605.	1.5	14
225	Swallowing difficulties from "DISH-phagia". <i>Journal of Rheumatology</i> , 2004, 31, 2526-7.	1.0	14
226	Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study. <i>Arthritis Research and Therapy</i> , 2015, 17, 136.	1.6	13
227	Comparative Effectiveness of Etanercept and Adalimumab in Patient Reported Outcomes and Injection-Related Tolerability. <i>PLoS ONE</i> , 2016, 11, e0149781.	1.1	13
228	Assessing Rheumatoid Arthritis Disease Activity With Patient-Reported Outcomes Measurement Information System Measures Using Digital Technology. <i>Arthritis Care and Research</i> , 2020, 72, 553-560.	1.5	13
229	Temporal Trends and Factors Associated with Bisphosphonate Discontinuation and Restart. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 478-487.	3.1	13
230	Using negative control outcomes to assess the comparability of treatment groups among women with osteoporosis in the United States. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 854-863.	0.9	13
231	Barriers to treatment optimization and achievement of patients' goals: perspectives from people living with rheumatoid arthritis enrolled in the ArthritisPower registry. <i>Arthritis Research and Therapy</i> , 2020, 22, 4.	1.6	13
232	Patient-Powered Research Networks of the Autoimmune Research Collaborative: Rationale, Capacity, and Future Directions. <i>Patient</i> , 2021, 14, 699-710.	1.1	13
233	Republished: The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis. <i>Postgraduate Medical Journal</i> , 2014, 90, 722-729.	0.9	12
234	Analysis of health care claims during the peri-transfer stage of transition from pediatric to adult care among juvenile idiopathic arthritis patients. <i>Pediatric Rheumatology</i> , 2016, 14, 49.	0.9	12

#	ARTICLE	IF	CITATIONS
235	Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) Study. <i>Contemporary Clinical Trials</i> , 2016, 50, 106-115.	0.8	12
236	Agreement between Rheumatologist and Patient-reported Adherence to Methotrexate in a US Rheumatoid Arthritis Registry. <i>Journal of Rheumatology</i> , 2016, 43, 1027-1029.	1.0	12
237	Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An OMERACT Special Interest Group Report. <i>Journal of Rheumatology</i> , 2017, 44, 1894-1898.	1.0	12
238	Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept. <i>Patient</i> , 2018, 11, 361-369.	1.1	12
239	Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women's Rheumatoid Arthritis Sequential Study Registry. <i>Arthritis Care and Research</i> , 2021, 73, 471-480.	1.5	12
240	Benefits of Methotrexate Use on Cardiovascular Disease Risk Among Rheumatoid Arthritis Patients Initiating Biologic Disease-modifying Antirheumatic Drugs. <i>Journal of Rheumatology</i> , 2021, 48, 804-812.	1.0	12
241	Association of cardiovascular disease and traditional cardiovascular risk factors with the incidence of dementia among patients with rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 292-298.	1.6	12
242	Meaningful Change Thresholds for Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue and Pain Interference Scores in Patients With Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 1239-1242.	1.0	12
243	Effects of the SARS-CoV-2 global pandemic on U.S. rheumatology outpatient care delivery and use of telemedicine: an analysis of data from the RISE registry. <i>Rheumatology International</i> , 2021, 41, 1755-1761.	1.5	12
244	Patient-Reported Nausea and Fatigue Related to Methotrexate: A Prospective, Self-Controlled Study in the ArthritisPower® Registry. <i>Rheumatology and Therapy</i> , 2022, 9, 207-221.	1.1	12
245	Improved Quality of Life With Anti-TNF Therapy Compared With Continued Corticosteroid Utilization in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 925-936.	0.9	11
246	Racial and ethnic differences in medication use among beneficiaries of social security disability insurance with rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 988-995.	1.6	11
247	Tough Choices: Exploring Medication Decision-Making During Pregnancy and Lactation Among Women With Inflammatory Arthritis. <i>ACR Open Rheumatology</i> , 2021, 3, 475-483.	0.9	11
248	Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment. <i>Arthritis Research and Therapy</i> , 2017, 19, 276.	1.6	10
249	Pregnancy, Periods, and "The Pill": Exploring the Reproductive Experiences of Women with Inflammatory Arthritis. <i>ACR Open Rheumatology</i> , 2019, 1, 125-132.	0.9	10
250	Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 1114-1124.	1.5	10
251	Secular Trends in the Incidence of Hip Fracture Among Nursing Home Residents. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1668-1675.	3.1	10
252	Effects of the COVID-19 Pandemic on Patients Living With Vasculitis. <i>ACR Open Rheumatology</i> , 2021, 3, 17-24.	0.9	10

#	ARTICLE	IF	CITATIONS
253	Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data. <i>Rheumatology and Therapy</i> , 2021, 8, 1661-1675.	1.1	10
254	Patient Perceptions and Preferences Regarding Telemedicine for Autoimmune Rheumatic Diseases Care During the COVID-19 Pandemic. <i>Arthritis Care and Research</i> , 2022, 74, 1049-1057.	1.5	10
255	A group randomized trial to improve safe use of nonsteroidal anti-inflammatory drugs. <i>American Journal of Managed Care</i> , 2005, 11, 537-43.	0.8	10
256	Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies. <i>RMD Open</i> , 2022, 8, e002103.	1.8	10
257	Safety of Biologic and Nonbiologic Disease-modifying Antirheumatic Drug Therapy in Veterans with Rheumatoid Arthritis and Hepatitis C Virus Infection. <i>Journal of Rheumatology</i> , 2017, 44, 565-570.	1.0	9
258	Factors associated with physicians' prescriptions for rheumatoid arthritis drugs not filled by patients. <i>Arthritis Research and Therapy</i> , 2018, 20, 79.	1.6	9
259	Tools and Methods for Real-World Evidence Generation. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 275-289.	0.8	9
260	Contraception methods used by women with rheumatoid arthritis and psoriatic arthritis. <i>Clinical Rheumatology</i> , 2019, 38, 1207-1212.	1.0	9
261	Patient and Rheumatologist Perspectives Regarding Challenges to Achieving Optimal Disease Control in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 933-941.	1.5	9
262	COVID-19 vaccine uptake and vaccine hesitancy in rheumatic disease patients receiving immunomodulatory therapies in community practice settings. <i>Arthritis and Rheumatology</i> , 2022, 74, 1091-1092.	2.9	9
263	Regional Variation in the Denial of Reimbursement for Bone Mineral Density Testing Among US Medicare Beneficiaries. <i>Journal of Clinical Densitometry</i> , 2008, 11, 568-574.	0.5	8
264	Validity of physician-reported hospitalized infections in a US arthritis registry. <i>Rheumatology</i> , 2009, 48, 1269-1272.	0.9	8
265	Improving osteoporosis care in high-risk home health patients through a high-intensity intervention. <i>Contemporary Clinical Trials</i> , 2012, 33, 206-212.	0.8	8
266	Risk of Cardiovascular Outcomes among Psoriasis Patients Treated with Biologics and Other Systemic Agents. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2016, 1, 128-137.	0.3	8
267	Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 757-769.	0.9	8
268	Mapping from the International Classification of Diseases (ICD) 9th to 10th Revision for Research in Biologics and Biosimilars Using Administrative Healthcare Data. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 770-777.	0.9	8
269	Real-world switch patterns and healthcare costs in biologic-naïve psoriasis patients initiating apremilast or biologics. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 767-779.	0.6	8
270	Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients. <i>Scientific Reports</i> , 2020, 10, 14607.	1.6	8

#	ARTICLE	IF	CITATIONS
271	Patterns of Tumor Necrosis Factor Inhibitor (TNF i) Biosimilar Use Across United States Rheumatology Practices. ACR Open Rheumatology, 2020, 2, 79-83.	0.9	8
272	Use of health plan combined with registry data to predict clinical trial recruitment. Clinical Trials, 2014, 11, 96-101.	0.7	7
273	An Internet-based Controlled Trial Aimed to Improve Osteoporosis Prevention among Chronic Glucocorticoid Users. Journal of Rheumatology, 2015, 42, 1478-1483.	1.0	7
274	Which patient reported outcome domains are important to the rheumatologists while assessing patients with rheumatoid arthritis?. BMC Rheumatology, 2019, 3, 36.	0.6	7
275	Evaluation of the Effect of Diabetes on Rheumatoid Arthritisâ€related Outcomes in an Electronic Health Recordâ€based Rheumatology Registry. Journal of Rheumatology, 2021, 48, 992-1001.	1.0	7
276	TNFi Cycling Versus Changing Mechanism of Action in TNFiâ€Experienced Patients: Result of the Corona CERTAIN Comparative Effectiveness Study. ACR Open Rheumatology, 2022, 4, 65-73.	0.9	7
277	Fractures and mortality in relation to different osteoporosis treatments. Clinical and Experimental Rheumatology, 2015, 33, 302-9.	0.4	7
278	Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatology and Therapy, 2022, 9, 243-263.	1.1	7
279	The Economic Benefit of Remission for Patients with Rheumatoid Arthritis. Rheumatology and Therapy, 2022, 9, 1329-1345.	1.1	7
280	Evaluation of a Methodologic Approach to Define an Inception Cohort of Rheumatoid Arthritis Patients Using Administrative Data. Arthritis Care and Research, 2018, 70, 1541-1545.	1.5	6
281	Development of algorithms for identifying fatal cardiovascular disease in <scp>Medicare</scp> claims. Pharmacoepidemiology and Drug Safety, 2018, 27, 740-750.	0.9	6
282	Defining and characterizing sustained remission in patients with rheumatoid arthritis. Clinical Rheumatology, 2018, 37, 885-893.	1.0	6
283	Assessing a novel way to measure three common rehabilitation outcome measures using a custom mobile phone application. Gait and Posture, 2019, 73, 246-250.	0.6	6
284	Views of primary care physicians and rheumatologists regarding screening and treatment of hyperlipidemia among patients with rheumatoid arthritis. BMC Rheumatology, 2020, 4, 14.	0.6	6
285	Barriers and facilitators for screening and treatment of hyperlipidemia among patients with inflammatory arthritis. BMC Rheumatology, 2020, 4, 26.	0.6	6
286	Comparative safety of flavocoxid vs prescription NSAIDs among osteoarthritis patients. Osteoarthritis and Cartilage, 2020, 28, 917-923.	0.6	6
287	Influence of Multimorbidity on New Treatment Initiation and Achieving Target Disease Activity Thresholds in Active Rheumatoid Arthritis: A Cohort Study Using the Rheumatology Informatics System for Effectiveness Registry. Arthritis Care and Research, 2023, 75, 231-239.	1.5	6
288	The Validity of Claims-Based Algorithms to Identify Serious Hypersensitivity Reactions and Osteonecrosis of the Jaw. PLoS ONE, 2015, 10, e0131601.	1.1	6

#	ARTICLE	IF	CITATIONS
289	Validation of an algorithm to identify incident interstitial lung disease in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2022, 24, 2.	1.6	6
290	Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor- ϵ inhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritis. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 101-109.	1.5	6
291	Trends in Hospitalization Rates, Major Causes of Hospitalization, and In-Hospital Mortality in Rheumatoid Arthritis in the United States From 2000 to 2014. <i>ACR Open Rheumatology</i> , 2020, 2, 715-724.	0.9	5
292	Enhancing Patient Understanding of Medication Risks and Benefits. <i>Arthritis Care and Research</i> , 2020, , .	1.5	5
293	Antiphospholipid Antibody Testing in a General Population Sample from the USA: An Administrative Database Study. <i>Scientific Reports</i> , 2020, 10, 3102.	1.6	5
294	Low Incidence of Inflammatory Bowel Disease Adverse Events in Adalimumab Clinical Trials Across Nine Different Diseases. <i>Arthritis Care and Research</i> , 2021, 73, 289-295.	1.5	5
295	Risk of Serious Infection With Low-dose Glucocorticoids in Patients With Rheumatoid Arthritis. <i>Epidemiology</i> , 2022, 33, 65-74.	1.2	5
296	Prevalence of Frailty in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis: Data from a National Claims Dataset. <i>ACR Open Rheumatology</i> , 2022, 4, 300-305.	0.9	5
297	Recombinant Zoster Vaccine Uptake and Risk of Flares Among Older Adults With Immune-Mediated Inflammatory Diseases in the US. <i>Arthritis and Rheumatology</i> , 2022, 74, 1833-1841.	2.9	5
298	Evaluating and improving the quality of care in rheumatic disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2004, 4, 429-439.	0.7	4
299	Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 285.	1.6	4
300	Trends of lymphoma incidence in US veterans with rheumatoid arthritis, 2002-2017. <i>RMD Open</i> , 2020, 6, e001241.	1.8	4
301	Evaluation of the impact of age and adiposity on a multi-biomarker disease activity score before and after adjustment. <i>Clinical Rheumatology</i> , 2021, 40, 2419-2426.	1.0	4
302	Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritis. <i>International Immunopharmacology</i> , 2021, 91, 107260.	1.7	4
303	The Annual Diagnostic Prevalence of Ankylosing Spondylitis and Axial Spondyloarthritis in the United States Using Medicare and MarketScan Databases. <i>ACR Open Rheumatology</i> , 2021, 3, 743-752.	0.9	4
304	Risk-benefit analysis of isoniazid monotherapy to prevent tuberculosis in patients with rheumatic diseases exposed to prolonged, high-dose glucocorticoids. <i>PLoS ONE</i> , 2020, 15, e0244239.	1.1	4
305	Patient Perspectives on Biologics for Axial Spondyloarthritis in a Cross-sectional Study in a Predominantly Female Population: Treatment Satisfaction, Wear-off Between Doses, and Use of Supplemental Medication. <i>Rheumatology and Therapy</i> , 2022, 9, 509-520.	1.1	4
306	Just the FRAX: Management of Glucocorticoid-Induced Osteoporosis. <i>Gastroenterology</i> , 2018, 154, 748-750.	0.6	3

#	ARTICLE	IF	CITATIONS
307	An Observational Study of Cardiovascular Risks Associated with Rheumatoid Arthritis Therapies: A Comparison of Two Analytical Approaches. , 2018, 22, 17-101.		3
308	Uptake and Clinical Utility of Multibiomarker Disease Activity Testing in the United States. Journal of Rheumatology, 2019, 46, 237-244.	1.0	3
309	A Novel Method to Combine Assessment of Benefit and Harm: Outcome Measures in Rheumatology 3 rd Methodology Applied to Two Active Comparator Trials. Arthritis Care and Research, 2019, 71, 319-322.	1.5	3
310	Reply to Serious Adverse Events With Romosozumab Use in Japanese Patients: Need for Clear Formulation of Contraindications Worldwide. Journal of Bone and Mineral Research, 2020, 35, 996-997.	3.1	3
311	Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis. RMD Open, 2021, 7, e001399.	1.8	3
312	Higher Serum Urate Levels Are Associated With an Increased Risk for Sudden Cardiac Death. Journal of Rheumatology, 2021, 48, 1745-1753.	1.0	3
313	Prevalence of Renal Impairment in a US Commercially Insured Rheumatoid Arthritis Population: A Retrospective Analysis. Rheumatology and Therapy, 2021, 8, 1383-1391.	1.1	3
314	Protocol for the pilot randomized trial of the CARdiovascular Risk assEssment for Rheumatoid Arthritis (CARE RA) intervention: a peer coach behavioral intervention. Pilot and Feasibility Studies, 2022, 8, 84.	0.5	3
315	Rheumatologist and Patient Mental Models for Treatment of Rheumatoid Arthritis Help Explain Low Treatment Target Rates. ACR Open Rheumatology, 2022, 4, 700-710.	0.9	3
316	Improving medical record retrieval for validation studies in Medicare data. Pharmacoepidemiology and Drug Safety, 2017, 26, 393-401.	0.9	2
317	Harnessing health plan enrollee data to boost membership in patient-powered research networks. BMC Health Services Research, 2020, 20, 462.	0.9	2
318	Reply. Arthritis and Rheumatology, 2021, 73, 1769-1770.	2.9	2
319	Development and validation of the Methotrexate Experience Questionnaire, a new methotrexate oral treatment adherence tool in rheumatoid arthritis. Journal of Patient-Reported Outcomes, 2021, 5, 69.	0.9	2
320	Treatment Satisfaction and Decision-making from the Patient Perspective in Axial Spondyloarthritis: Real-World Data from a Descriptive Cross-sectional Survey Study from the ArthritisPower Registry. ACR Open Rheumatology, 2021, , .	0.9	2
321	COVID-19 Update for the GRAPPA 2021 Annual Meeting: Focus on COVID-19 Vaccination. Journal of Rheumatology, 2022, , jrheum.211319.	1.0	2
322	Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of Baricitinib. ACR Open Rheumatology, 2022, 4, 254-258.	0.9	2
323	Impact of Methotrexate Discontinuation, Interruption, or Persistence in US Patients with Rheumatoid Arthritis Initiating Tofacitinib+Oral Methotrexate Combination. Clinical Therapeutics, 2022, , .	1.1	2
324	Epidemiologic Research of Invasive Fungal Infections Using Large Healthcare Databases. Current Fungal Infection Reports, 2013, 7, 320-325.	0.9	1

#	ARTICLE	IF	CITATIONS
325	Reply. Arthritis and Rheumatology, 2018, 70, 795-796.	2.9	1
326	Reply. Arthritis and Rheumatology, 2018, 70, 320-320.	2.9	1
327	The promise and perils of "Big Data": focus on spondyloarthritis. Current Opinion in Rheumatology, 2019, 31, 355-361.	2.0	1
328	Response to: "Can we prescribe TMP/SMX prophylaxis without any concerns equally for all patients with rheumatic disease?" by Suyama and Okada. Annals of the Rheumatic Diseases, 2019, 78, e18-e18.	0.5	1
329	Evaluation of an Intervention to Support <scp>Patient-Rheumatologist</scp> Conversations About Escalating Treatment in Patients with Rheumatoid Arthritis: A <scp>Proof-of-Principle</scp> Study. ACR Open Rheumatology, 2022, 4, 279-287.	0.9	1
330	The Interface Between Digital Health and Rheumatology. Rheumatic Disease Clinics of North America, 2019, 45, xv-xvi.	0.8	0
331	Reply. Arthritis Care and Research, 2020, 72, 736-738.	1.5	0
332	Reply. Arthritis and Rheumatology, 2021, 73, 1771-1772.	2.9	0
333	Association between chronic obstructive pulmonary disease, smoking, and interstitial lung disease onset in rheumatoid arthritis. Clinical and Experimental Rheumatology, 2021, , .	0.4	0
334	P204 Filgotinib demonstrates clinical efficacy in rheumatoid arthritis independent of smoking status: a post-hoc subgroup analysis of three Phase 3 clinical trials. Rheumatology, 2022, 61, .	0.9	0